

Chapter 5

Cancer survival in Hong Kong SAR, China, 1996–2001

Law SC and Mang OW

Abstract

The Hong Kong cancer registry was established in 1963, and cancer registration is done by passive and active methods. The registry contributed data on 45 cancer sites or types registered during 1996–2001 for this survival study. Follow-up has been carried out by passive methods with median follow-up ranging from 4–60 months. The proportion of cases with histologically verified cancer diagnosis ranged from 38–100%; death certificates only (DCOs) ranged from 0–11%; 83–99% of total registered cases were included for survival analysis. The 5-year age-standardized relative survival exceeded 100% for lip and non-melanoma skin followed by thyroid (94%) and testicular (92%) cancers. The corresponding survival for common cancers were breast (90%), colon (61%), liver and lung (22%), nasopharynx (70%), rectum (59%) and stomach (39%). The 5-year relative survival by age group showed a decreasing trend with increasing age groups for most cancers. A decreasing survival with increasing clinical extent of disease was noted.

Hong Kong cancer registry

The Hong Kong cancer registry was established in 1963 and is currently based at the clinical oncology department, Queen Elizabeth Hospital, Hospital Authority of Hong Kong. The registry has been contributing data to the quinquennial IARC publication *Cancer Incidence in Five Continents* since Vol IV [1]. Cancer notification is by an administrative order without a specific law. Hence, cancer registration is done by passive and active methods. The principal sources of information on cancer cases are the records in more than 50 institutions comprising the hospitals in public and private sectors, radiation centres and pathology laboratories as well as voluntary notifications from private practitioners. The registry covers the entire country (1104 km²) and a population of about 6.9 million with a sex ratio of 1076 females to 1000 males in 2004. The average annual age-standardized incidence rate is 265 per 100 000 among males and 197 per 100 000 among females, with a lifetime cumulative risk of one in four of developing cancer in the period 1998–2002. The top ranking cancers among males are lung followed by liver and colon. Among females, the order is breast, lung and colon [2].

The registry contributed data on survival from 45 cancer sites or types for the first time in this volume of the IARC publication *Cancer survival in Africa, Asia, the Caribbean and Central America*.

Data quality indices (Table 1)

The proportion of cases with histologically verified cancer diagnosis in our series is 86%, varying from 38% (cancer of the pancreas) to 100% (melanoma of the skin and kidney, and mesothelioma). The proportion of cases registered as death certificates only (DCOs) is 1%, ranging between 0% for many cancers and 11% for unspecified leukaemia. Cases excluded without any follow-up are negligible. Thus, 83–99% of the total cases registered are included in the estimation of the survival probability (see note on next page).

Outcome of follow-up (Table 2)

Follow-up has been carried out by passive methods. This included obtaining cancer mortality information from the death certificates in births, deaths and marriages registry of the Government. The mortality data are periodically matched with the incident cancer database. Unmatched incident cases are then presumed to be alive on the last date of the year for which the mortality data is fully available.


The closing date of follow-up is 31st December 2003. The median follow-up ranged from four months in cancer of the pancreas and unspecified leukaemia to 60 months in lip cancer.

Survival statistics

All ages and both sexes together (Table 3)

The 5-year relative survival is the highest in non-melanoma skin and lip cancers (102%) followed by thyroid (94%), testis (90%) and breast (90%). The lowest survival is encountered with pancreatic cancer (17%) preceded by lung (21%), liver and gallbladder (22%) and unspecified leukaemia (25%). Salivary gland (83%) and nasopharynx (75%) among other head and neck cancers and colon and rectum (61%) among gastrointestinal cancers have higher survival rates than others. Survival from cancers of the urinary system is 76% for urinary bladder and 66% for kidney. Hodgkin lymphoma had a better survival (84%) than non-Hodgkin lymphoma (56%). The survival figures for leukaemias are lymphoid (60%) and myeloid (34%).

Figure 1a. Top ten cancers (ranked by survival), Hong Kong SAR, China, 1996–2001




The 5-year age-standardized relative survival (ASRS) probability for all ages together is generally lesser than or similar to the corresponding unadjusted one for most cancers. Also, the 5-year ASRS (0–74 years of age) is generally higher than or similar to the corresponding ASRS (all ages) for a majority of cancers.

Sex

Male (Table 4a)

The top five cancers ranked on the 5-year relative survival probabilities are lip (102%), non-melanoma skin (101%), breast (100%), testis and thyroid (90%). Survival from breast cancer is noticeably higher among males than females.


Figure 1b. Top five cancers (ranked by survival), Male, Hong Kong SAR, China, 1996–2001



Female (Table 4a)

The highest 5-year relative survival probability is observed for non-melanoma skin cancer (104%), followed by lip (102%), thyroid (95%), Hodgkin lymphoma (92%) and salivary gland (90%). The survival is distinctly higher among females than males in most of the head and neck cancers, oesophagus, nose and sinuses, mesothelioma, adrenal glands, Hodgkin lymphoma and unspecified leukaemia.

Figure 1c. Top five cancers (ranked by survival), Female, Hong Kong SAR, China, 1996–2001



Age group (Table 4b)


The 5-year relative survival by age group reveals an inverse relationship: a decreasing survival with increasing age at diagnosis for cancers of the oral cavity, nasopharynx, liver, nose and sinuses, lung,

melanoma skin, soft tissue, cervix, ovary, bladder, thyroid, non-Hodgkin lymphoma and myeloid leukaemia. In the rest, it is observed to be fluctuating.

Extent of disease (Table 5)

A high proportion of cases of breast cancer is classified under the regional category of extent of disease (35%) followed by 12% in localized and 1% in distant metastasis categories. However, the extent of disease is unknown in 52%. The 5-year absolute survival by extent of disease followed the expected pattern: highest for localized cases followed by regional and distant metastasis cases among known categories of extent of disease. It is 83% for unknown category.

Figure 2. Absolute survival by extent of disease, Hong Kong SAR, China, 1996–2001, cancer of the breast



Note: The extent of disease of the breast cancer data presented here is a summary of a pilot study carried out retrospectively by the registry in 2003. The project was conducted on a cohort of breast cancer cases diagnosed between 1996 and 2001. Information on about 80% of cases was audited and updated. Follow-up was done passively by matching with the death register. Owing to technical difficulties, we made an assumption that each ever-registered case was alive if not known to be dead. The possibility exists that some patients (especially for distant-staged groups) seek more aggressive treatment outside Hong Kong and are eventually lost to follow-up or die in other regions without making death registration here. This may have inflated survival rates. The much lower proportion of patients with distant tumours may also lead to a higher overall relative survival in this category of extent of disease. Since information is not fully available on the variables influencing survival, this is of particular concern in the above survival comparisons. One should take account of these differences when comparing these results with other findings.

References

1. Parkin DM, Whelan SL, Ferlay J and Storm H. *Cancer Incidence in Five Continents, Vol I to VIII: IARC Cancerbase No. 7*. IARCPress, Lyon, 2005.
2. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P. *Cancer Incidence in Five Continents, Vol. IX: IARC Scientific Publications No. 160*. IARCPress, Lyon, 2007.

Table 1. Data quality indices - Proportion of histologically verified and death certificate only cases, number and proportion of included and excluded cases by site: Hong Kong SAR, China, 1996–2001 cases followed-up until 2003

Site	ICD-10	Total registered	%		Excluded cases					Included cases	
			HV	DCO	DCO	Follow-up	Others	Total	%	No.	%
Lip	C00	47	85.1	2.1	1	0	4	5	10.6	42	89.4
Tongue	C01-02	737	92.8	0.3	2	0	58	60	8.1	677	91.9
Oral cavity	C03-06	605	94.0	0.5	3	0	41	44	7.3	561	92.7
Salivary gland	C07-08	347	91.1	0.0	0	0	17	17	4.9	330	95.1
Oropharynx	C09-10	237	92.8	0.4	1	0	17	18	7.6	219	92.4
Nasopharynx	C11	6 746	93.9	0.3	18	0	135	153	2.3	6 593	97.7
Hypopharynx	C12-13	402	94.8	0.5	2	0	40	42	10.4	360	89.6
Oesophagus	C15	3 054	92.8	1.0	32	3	187	222	7.3	2 832	92.7
Stomach	C16	6 209	92.4	1.0	63	2	265	330	5.3	5 879	94.7
Small intestine	C17	258	89.1	1.9	5	0	14	19	7.4	239	92.6
Colon	C18	11 685	90.4	1.1	134	7	519	660	5.6	11 025	94.4
Rectum, anus	C19-21	6 567	92.3	0.8	52	4	319	375	5.7	6 192	94.3
Liver	C22	9 920	60.3	4.0	392	10	262	664	6.7	9 256	93.3
Gall bladder	C23-24	1 702	61.7	2.3	39	0	62	101	5.9	1 601	94.1
Pancreas	C25	2 042	38.2	6.3	128	4	109	241	11.8	1 801	88.2
Nose/Sinuses	C30-31	309	90.0	0.6	2	0	19	21	6.8	288	93.2
Larynx	C32	1 284	92.3	0.5	6	0	68	74	5.8	1 210	94.2
Lung	C33-34	22 667	77.1	2.2	503	10	1023	1536	6.8	21 131	93.2
Other thoracic organs	C37-38	250	78.8	1.6	4	0	16	20	8.0	230	92.0
Bone	C40-41	280	80.0	2.1	6	0	18	24	8.6	256	91.4
Melanoma of skin	C43	276	100.0	0.0	0	0	15	15	5.4	261	94.6
Other skin	C44	2 719	97.1	0.1	2	0	131	133	4.9	2 586	95.1
Mesothelioma	C45	55	100.0	0.0	0	1	4	5	9.1	50	90.9
Connective tissue	C47+C49	1 025	95.1	0.7	7	1	47	55	5.4	970	94.6
Breast	C50	10 556	96.4	0.3	36	1	407	444	4.2	10 112	95.8
Vulva, vagina, other	C51-52+C57	256	91.4	0.0	0	0	24	24	9.4	232	90.6
Cervix	C53	2 727	95.8	0.2	5	0	98	103	3.8	2 624	96.2
Corpus uteri	C54	1 990	97.7	0.1	1	0	126	127	6.4	1 863	93.6
Ovary	C56	1 949	90.2	0.9	18	0	100	118	6.1	1 831	93.9
Penis	C60	163	95.7	0.0	0	0	2	2	1.2	161	98.8
Prostate	C61	3 441	90.7	0.5	17	1	217	235	6.8	3 206	93.2
Testis	C62	389	97.2	0.3	1	0	5	6	1.5	383	98.5
Kidney	C64	969	100.0	0.0	0	0	55	55	5.7	914	94.3
Urinary bladder	C67	3 750	92.3	0.4	15	0	261	276	7.4	3 474	92.6
Other urinary organs	C68	776	64.3	3.0	23	0	42	65	8.4	711	91.6
Eye	C69	66	92.4	1.5	1	0	0	1	1.5	65	98.5
Brain & nervous system	C70-72	1 349	82.1	3.6	49	0	31	80	5.9	1 269	94.1
Thyroid	C73	2 309	96.9	0.3	6	0	68	74	3.2	2 235	96.8
Adrenal gland, other	C74-75	173	67.6	8.1	14	0	0	14	8.1	159	91.9
Hodgkin lymphoma	C81	268	97.8	0.4	1	0	10	11	4.1	257	95.9
Non-Hodgkin lymphoma	C82-85+C96	3 516	95.3	0.9	32	3	163	198	5.6	3 318	94.4
Multiple myeloma	C90	857	90.4	2.5	21	0	40	61	7.1	796	92.9
Lymphoid leukaemia	C91	596	94.8	0.5	3	0	32	35	5.9	561	94.1
Myeloid leukaemia	C92-94	1 470	87.5	1.8	26	0	55	81	5.5	1 389	94.5
Leukaemia unspecified	C95	170	73.5	10.6	18	1	10	29	17.1	141	82.9

HV: histologically verified; DCO: death certificate only

Table 2. Number and proportion of cases by vital status and median follow-up (in months) by site: Hong Kong SAR, China, 1996–2001 cases followed-up until 2003

Site	ICD-10	Cases included	Dead		Alive		Complete FU		Median FU (in months)
			No.	%	No.	%	No.	%	
Lip	C00	42	6	14.3	36	85.7	42	100.0	59.6
Tongue	C01-02	677	288	42.5	389	57.5	677	100.0	41.6
Oral cavity	C03-06	561	278	49.6	283	50.4	561	100.0	34.5
Salivary gland	C07-08	330	83	25.2	247	74.8	330	100.0	54.8
Oropharynx	C09-10	219	130	59.4	89	40.6	219	100.0	27.0
Nasopharynx	C11	6 593	1 902	28.8	4 691	71.2	6 593	100.0	48.7
Hypopharynx	C12-13	360	268	74.4	92	25.6	360	100.0	16.4
Oesophagus	C15	2 832	2 216	78.2	616	21.8	2 832	100.0	9.7
Stomach	C16	5 879	4 009	68.2	1 870	31.8	5 879	100.0	15.6
Small intestine	C17	239	151	63.2	88	36.8	239	100.0	21.1
Colon	C18	11 025	5 506	49.9	5 519	50.1	11 025	100.0	35.2
Rectum, anus	C19-21	6 192	2 984	48.2	3 208	51.8	6 192	100.0	35.4
Liver	C22	9 256	7 445	80.4	1 811	19.6	9 256	100.0	5.6
Gall bladder	C23-24	1 601	1 303	81.4	298	18.6	1 601	100.0	7.0
Pancreas	C25	1 801	1 552	86.2	249	13.8	1 801	100.0	4.4
Nose/Sinuses	C30-31	288	119	41.3	169	58.7	288	100.0	41.6
Larynx	C32	1 210	507	41.9	703	58.1	1 210	100.0	41.6
Lung	C33-34	21 131	17 393	82.3	3 738	17.7	21 131	100.0	8.1
Other thoracic organs	C37-38	230	91	39.6	139	60.4	230	100.0	38.1
Bone	C40-41	256	77	30.1	179	69.9	256	100.0	49.7
Melanoma of skin	C43	261	124	47.5	137	52.5	261	100.0	33.5
Other skin	C44	2 586	519	20.1	2 067	79.9	2 586	100.0	50.7
Mesothelioma	C45	50	40	80.0	10	20.0	50	100.0	11.0
Connective tissue	C47+C49	970	341	35.2	629	64.8	970	100.0	42.6
Breast	C50	10 112	1 649	16.3	8 463	83.7	10 112	100.0	50.7
Cervix	C53	2 624	756	28.8	1 868	71.2	2 624	100.0	48.7
Corpus uteri	C54	1 863	372	20.0	1 491	80.0	1 863	100.0	48.7
Ovary	C56	1 831	653	35.7	1 178	64.3	1 831	100.0	42.6
Vulva/vagina, etc.	C57;C51-52	232	96	41.4	136	58.6	232	100.0	37.8
Penis	C60	161	60	37.3	101	62.7	161	100.0	44.6
Prostate	C61	3 206	1 271	39.6	1 935	60.4	3 206	100.0	38.2
Testis	C62	383	71	18.5	312	81.5	383	100.0	54.8
Kidney	C64	914	378	41.4	536	58.6	914	100.0	37.5
Urinary bladder	C67	3 474	1 438	41.4	2 036	58.6	3 474	100.0	40.5
Other urinary organs	C68	711	407	57.2	304	42.8	711	100.0	26.3
Eye	C69	65	12	18.5	53	81.5	65	100.0	49.7
Brain & nervous system	C70-72	1 269	709	55.9	560	44.1	1 269	100.0	27.4
Thyroid	C73	2 235	240	10.7	1 995	89.3	2 235	100.0	58.9
Adrenal gland, other	C74-75	159	51	32.1	108	67.9	159	100.0	49.7
Hodgkin lymphoma	C81	257	50	19.5	207	80.5	257	100.0	48.7
Non-Hodgkin lymphoma	C82-85+C96	3 318	1 672	50.4	1 646	49.6	3 318	100.0	32.5
Multiple myeloma	C90	796	571	71.7	225	28.3	796	100.0	20.4
Lymphoid leukaemia	C91	561	242	43.1	319	56.9	561	100.0	36.5
Myeloid leukaemia	C92-94	1 389	935	67.3	454	32.7	1 389	100.0	15.1
Leukaemia unspecified	C95	141	109	77.3	32	22.7	141	100.0	4.5

FU: follow-up

Table 3. Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival by site: Hong Kong SAR, China, 1996–2001 cases followed-up until 2003

Site	ICD-10	Cases included	% Absolute survival			% Relative survival			% ASRS at 5-years	
			1-year	3-year	5-year	1-year	3-year	5-year	all ages	0-74 years
Lip	C00	42	97.6	92.6	84.9	100.6	102.0	101.6	103.6	100.3
Tongue	C01-02	677	80.9	61.7	56.8	83.0	66.5	64.6	63.7	64.0
Oral cavity	C03-06	561	70.9	57.8	50.2	73.7	64.3	60.2	62.8	64.5
Salivary gland	C07-08	330	90.6	81.3	75.5	92.5	86.1	83.2	80.3	81.8
Oropharynx	C09-10	219	68.5	46.6	40.1	70.3	50.1	45.1	45.9	47.8
Nasopharynx	C11	6 593	92.1	78.5	70.2	93.2	81.4	74.6	69.6	74.0
Hypopharynx	C12-13	360	60.8	31.7	22.5	63.0	35.4	27.1	25.5	24.1
Oesophagus	C15	2 832	43.9	25.3	20.9	45.6	28.4	25.6	26.1	26.4
Stomach	C16	5 879	54.5	35.9	30.8	57.0	40.8	38.2	38.7	41.5
Small intestine	C17	239	57.7	40.4	35.7	59.8	44.4	41.7	41.4	48.5
Colon	C18	11 025	74.8	57.2	48.9	78.2	65.2	61.3	61.0	63.2
Rectum, anus	C19-21	6 192	79.2	59.3	49.9	82.4	66.4	60.6	59.2	63.4
Liver	C22	9 256	36.9	23.0	18.9	38.0	24.9	21.6	22.4	24.6
Gall bladder	C23-24	1 601	38.0	21.7	17.8	40.1	25.0	22.4	26.1	29.7
Pancreas	C25	1 801	27.3	15.2	13.7	28.4	17.0	16.5	17.2	19.9
Nose/Sinuses	C30-31	288	78.5	63.5	58.6	80.8	69.0	67.7	66.5	70.2
Larynx	C32	1 210	84.5	66.0	57.9	88.0	74.7	71.9	72.4	73.4
Lung	C33-34	21 131	39.6	20.8	17.0	41.4	23.6	21.1	22.1	25.1
Other thoracic organs	C37-38	230	75.2	63.0	60.2	76.6	65.7	64.7	54.9	72.2
Bone	C40-41	256	87.9	73.8	69.3	88.9	76.0	72.7	68.8	70.1
Melanoma of skin	C43	261	83.5	56.8	49.5	86.5	63.1	59.2	60.1	61.7
Other skin	C44	2 586	94.7	86.0	79.1	99.6	100.3	102.4	101.1	100.1
Mesothelioma	C45	50	48.0	28.0	23.6	49.6	30.1	26.2	28.0	38.1
Connective tissue	C47	970	82.0	69.4	63.6	83.6	73.3	69.4	62.8	66.5
Breast	C50	10 112	95.6	87.4	82.4	97.1	91.8	89.8	90.0	89.6
Vulva, vagina, other	C51-52+C57	232	84.1	62.4	57.6	87.2	69.6	69.5	71.0	73.4
Cervix	C53	2 624	88.8	76.1	70.4	90.3	80.0	76.8	77.3	79.5
Corpus uteri	C54	1 863	91.4	82.3	79.4	92.7	86.0	85.6	84.1	85.1
Ovary	C56	1 831	83.0	69.0	63.5	84.2	71.7	67.6	63.6	67.3
Penis	C60	161	87.6	72.9	64.1	92.0	85.1	83.5	83.9	86.8
Prostate	C61	3 206	87.8	69.2	55.6	93.8	85.2	79.9	79.3	78.2
Testis	C62	383	94.8	86.9	80.8	96.8	92.6	90.0	91.9	92.1
Kidney	C64	914	77.8	64.4	57.8	80.0	69.8	66.3	65.5	70.5
Urinary bladder	C67	3 474	81.3	65.7	57.8	85.7	76.9	75.5	75.9	81.2
Other urinary organs	C68	711	62.9	47.1	42.5	65.6	52.9	51.6	54.0	61.0
Eye	C69	65	93.8	85.9	78.6	96.0	90.8	85.4	59.4	51.9
Brain & nervous system	C70-72	1 269	65.7	49.0	43.9	66.8	50.7	46.4	46.7	48.7
Thyroid	C73	2 235	93.5	91.3	89.0	94.6	94.3	94.1	93.7	95.1
Adrenal gland, other	C74-75	159	81.8	71.5	68.0	82.8	73.5	71.1	57.8	71.2
Hodgkin lymphoma	C81	257	89.1	82.6	79.8	90.3	85.2	84.1	85.6	87.4
Non-Hodgkin lymphoma	C82-85+C96	3 318	67.4	54.1	48.9	69.5	58.8	56.1	61.6	64.7
Multiple myeloma	C90	796	62.4	37.6	25.1	65.1	42.4	31.0	34.8	37.8
Lymphoid leukaemia	C91	561	77.7	60.9	54.9	79.3	64.3	60.0	56.7	59.1
Myeloid leukaemia	C92-94	1 389	55.0	36.9	31.4	56.4	38.8	33.9	36.0	42.3
Leukaemia unspecified	C95	141	32.6	23.3	23.3	33.9	25.0	25.4	31.4	36.8

ASRS: age-standardized relative survival

Table 4a. Site-wise number of cases, 5-year absolute and relative survival by sex: Hong Kong SAR, China, 1996–2001 cases followed-up until 2003

Site	ICD-10	Cases included	Male			Female		
			% 5-year survival			% 5-year survival		
			No.	Abs	Rel	No.	Abs	Rel
Lip	C00	42	25	84.0	101.7	17	87.1	102.1
Tongue	C01-02	677	438	50.1	57.6	239	69.3	77.5
Oral cavity	C03-06	561	378	45.9	55.9	183	59.5	69.0
Salivary gland	C07-08	330	180	68.2	77.0	150	83.9	90.3
Oropharynx	C09-10	219	180	33.1	37.8	39	71.0	77.0
Nasopharynx	C11	6 593	4 751	67.6	72.2	1 842	77.0	80.7
Hypopharynx	C12-13	360	335	20.4	24.7	25	50.3	57.8
Oesophagus	C15	2 832	2 290	18.9	23.2	542	29.3	35.7
Stomach	C16	5 879	3 709	31.3	39.2	2 170	30.0	36.4
Small intestine	C17	239	126	34.8	41.6	113	36.8	41.7
Colon	C18	11 025	5 819	47.6	60.7	5 206	50.3	61.8
Rectum, anus	C19-21	6 192	3 638	48.2	59.2	2 554	52.5	62.6
Liver	C22	9 256	7 223	18.9	21.5	2 033	19.1	21.8
Gall bladder	C23-24	1 601	758	17.5	22.5	843	18.0	22.4
Pancreas	C25	1 801	989	14.9	17.9	812	12.2	14.7
Nose/Sinuses	C30-31	288	178	56.2	63.9	110	62.6	74.1
Larynx	C32	1 210	1 130	57.7	71.7	80	61.7	75.1
Lung	C33-34	21 131	14 375	16.8	21.0	6 756	17.5	21.2
Other thoracic organs	C37-38	230	134	59.8	64.4	96	60.4	64.8
Bone	C40-41	256	140	66.7	70.2	116	72.5	75.8
Melanoma of skin	C43	261	141	45.3	55.7	120	54.4	63.2
Other skin	C44	2 586	1 207	78.7	100.7	1 379	79.4	103.9
Mesothelioma	C45	50	30	16.0	18.5	20	35.0	37.6
Connective tissue	C47	970	511	58.2	65.1	459	69.7	74.2
Breast	C50	10 112	63	77.3	99.8	10 049	82.4	89.7
Vulva, vagina, other	C51-52+C57	232				232	57.6	69.5
Cervix	C53	2 624				2 624	70.4	76.8
Corpus uteri	C54	1 863				1 863	79.4	85.6
Ovary	C56	1 831				1 831	63.5	67.6
Penis	C60	161	161	64.1	83.5			
Prostate	C61	3 206	3 206	55.6	79.9			
Testis	C62	383	383	80.8	90.0			
Kidney	C64	914	592	56.0	64.9	322	61.0	68.8
Urinary bladder	C67	3 474	2 620	58.4	76.5	854	55.8	72.4
Other urinary organs	C68	711	440	43.5	53.8	271	40.9	48.3
Eye	C69	65	33	76.0	85.3	32	82.3	87.0
Brain & nervous system	C70-72	1 269	765	40.2	42.9	504	49.4	51.7
Thyroid	C73	2 235	488	82.2	89.6	1 747	91.0	95.3
Adrenal gland, other	C74-75	159	97	64.0	67.0	62	74.4	77.7
Hodgkin lymphoma	C81	257	153	74.2	78.3	104	87.9	92.4
Non-Hodgkin lymphoma	C82-85+C96	3 318	1 900	47.2	54.9	1 418	51.3	57.7
Multiple myeloma	C90	796	439	25.3	31.7	357	25.0	30.4
Lymphoid leukaemia	C91	561	310	54.6	60.7	251	55.2	58.9
Myeloid leukaemia	C92-94	1 389	766	30.0	32.7	623	33.2	35.2
Leukaemia unspecified	C95	141	70	15.6	17.2	71	31.0	33.6

Abs: absolute survival; Rel: relative survival

Table 4b. Site-wise number of cases and relative survival by age group: Hong Kong SAR, China, 1996–2001 cases followed-up until 2003

Site	ICD-10	Cases included	Number of cases by age group					Relative survival by age group				
								% 5-year survival				
			< 45	45-54	55-64	65-74	> 75	< 45	45-54	55-64	65-74	> 75
Lip	C00	42	8	6	6	12	10	101.1	102.8	110.3	71.8	119.7
Tongue	C01-02	677	139	119	151	170	98	76.8	63.7	58.0	67.1	63.2
Oral cavity	C03-06	561	50	75	127	171	138	84.8	61.8	59.2	58.7	52.8
Salivary gland	C07-08	330	118	63	55	55	39	90.4	88.2	74.7	76.4	73.0
Oropharynx	C09-10	219	30	45	61	58	25	70.2	61.2	32.4	35.6	38.2
Nasopharynx	C11	6 593	2 726	1 744	1 094	759	270	80.8	76.1	67.5	64.0	57.1
Hypopharynx	C12-13	360	20	69	94	107	70	15.2	25.5	25.2	29.5	35.6
Oesophagus	C15	2 832	100	364	696	995	677	33.5	26.1	23.0	26.8	26.0
Stomach	C16	5 879	530	640	1 021	1 733	1 955	43.0	43.0	41.9	39.3	32.2
Small intestine	C17	239	36	42	41	57	63	44.5	47.5	53.3	47.4	21.5
Colon	C18	11 025	754	1 047	1 889	3 636	3 699	64.3	63.3	64.0	62.3	58.1
Rectum, anus	C19-21	6 192	508	718	1 238	2 076	1 652	62.5	65.5	64.7	61.8	53.1
Liver	C22	9 256	1 163	1 720	2 243	2 605	1 525	33.8	25.8	20.6	18.5	13.1
Gall bladder	C23-24	1 601	59	110	210	520	702	35.1	35.7	26.6	24.4	16.1
Pancreas	C25	1 801	93	187	348	600	573	25.1	22.6	23.1	13.0	12.5
Nose/Sinuses	C30-31	288	50	55	57	69	57	82.3	76.8	67.1	58.6	56.8
Larynx	C32	1 210	34	141	309	445	281	73.7	70.6	78.5	69.0	69.2
Lung	C33-34	21 131	904	1 834	4 063	7 490	6 840	30.4	28.9	25.9	20.2	15.5
Other thoracic organs	C37-38	230	90	38	31	50	21	63.0	83.9	74.2	71.4	6.6
Bone	C40-41	256	153	36	27	25	15	75.9	68.4	74.7	62.1	72.8
Melanoma of skin	C43	261	55	38	41	60	67	68.2	60.4	58.2	55.5	51.2
Other skin	C44	2 586	212	250	371	730	1 023	96.0	99.8	100.8	103.7	105.6
Mesothelioma	C45	50	5	6	12	16	11	80.7	17.0	27.1	29.4	0.0
Connective tissue	C47	970	415	146	127	160	122	80.4	68.8	61.0	58.8	51.7
Breast	C50	10 112	3 226	2 689	1 508	1 399	1 290	88.5	90.5	89.1	90.4	93.6
Vulva, vagina, other	C51-52+C57	232	35	23	25	74	75	71.6	65.7	84.6	69.3	64.8
Cervix	C53	2 624	758	563	420	508	375	83.6	80.1	77.4	73.4	60.6
Corpus uteri	C54	1 863	334	631	400	321	177	93.4	87.1	85.9	76.1	83.5
Ovary	C56	1 831	649	422	277	287	196	84.1	67.8	60.6	50.7	45.8
Penis	C60	161	16	11	28	54	52	75.4	94.7	90.6	87.2	72.6
Prostate	C61	3 206	3	36	352	1 329	1 486	68.0	70.2	71.0	82.9	80.2
Testis	C62	383	237	41	18	33	54	94.2	92.1	56.7	93.8	75.9
Kidney	C64	914	128	193	180	261	152	81.8	64.4	65.6	68.4	50.0
Urinary bladder	C67	3 474	141	252	568	1 195	1 318	92.9	85.1	79.4	77.3	67.7
Other urinary organs	C68	711	53	80	126	224	228	61.2	65.8	68.2	50.8	34.4
Eye	C69	65	43	1	4	9	8	96.8	0.0	81.9	43.6	97.3
Brain & nervous system	C70-72	1 269	585	198	175	203	108	66.4	37.9	31.8	20.7	21.1
Thyroid	C73	2 235	1 102	419	302	258	154	99.7	98.9	90.5	83.8	60.8
Adrenal gland, other	C74-75	159	97	25	17	14	6	71.1	90.5	66.6	62.2	22.5
Hodgkin lymphoma	C81	257	157	27	24	31	18	95.2	80.2	76.1	50.5	57.2
Non-Hodgkin lymphoma	C82-85+C96	3 318	714	457	585	821	741	70.0	69.1	60.5	49.3	36.0
Multiple myeloma	C90	796	35	92	137	279	253	46.7	53.1	29.9	30.4	21.4
Lymphoid leukaemia	C91	561	329	37	51	68	76	69.8	46.5	39.2	44.5	46.0
Myeloid leukaemia	C92-94	1 389	536	159	166	288	240	52.9	42.6	30.4	14.7	7.4
Leukaemia unspecified	C95	141	40	19	11	31	40	47.9	37.8	19.3	11.2	

Table 5. Proportion of cases and 5-year absolute survival by extent of disease of breast cancer: Hong Kong SAR, China, 1996–2001

Site	ICD-10	Cases included	% of cases by extent of disease				% 5-year absolute survival			
			Localized	Regional	Dist. met.	Unknown	Localized	Regional	Dist. met.	Unknown
Breast	C50	10 112	12.2	34.6	1.5	51.7	94.9	79.1	31.8	82.7

